Upregulation of the signal transducers and activators of transcription 3 (STAT3) pathway in lymphatic metastases of papillary thyroid cancer

International Journal of Clinical and Experimental Pathology

Volumn 4, Issue 4, 2011, Pages 356-362

  Zhang, Jingdong ^a   Gill, Anthony ^b   Atmore, Bryn ^b   Johns, Amber ^c   Delbridge, Leigh ^b   Lai, Raymond ^d   McMullen, Todd ^a  

^a CROSS CANCER INSTITUTE   (Canada)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Immunohistochemistry; Metastases; Papillary thyroid cancer; Stat3

Indexed keywords

STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER STAGING; CHEMISTRY; CHI SQUARE DISTRIBUTION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; METASTASIS; MIDDLE AGED; PHOSPHORYLATION; SIGNAL TRANSDUCTION; THYROID TUMOR; THYROIDECTOMY; TUMOR VOLUME; UPREGULATION;

CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; THYROID NEOPLASMS; THYROIDECTOMY; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 80051698148     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Pai SI, Tufano RP. Reoperation for recurrent/ persistent well-differentiated thyroid cancer. Otolaryngol Clin North Am. 2010; 43:353-63
2. Lundgren CI, Hall P, Dickman PW, Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a populationbased, nested case-control study. Cancer 2006; 106:524-531
3. Hughes CJ, Shaha AR, Shah JP, Loree TR. Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis. Head Neck 1996; 18:127-132
4. Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer, World J Surg 2002;26:22-28.
5. Coburn M, Teates D, Wanebo JH. Recurrent thyroid cancer. Role of surgery versus radioactive iodine (I131), Ann Surg 1994; 219:587-593.
6. Rotstein L. The role of lymphadenectomy in the management of papillary carcinoma of the thyroid. J Surg Oncol 2009; 99:186-188.
7. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Thyroid 2009; 19:1167-1214.
8. Udelsman R. Treatment of persistent or recurrent papillary carcinoma of the thyroid--the good, the bad, and the unknown. J Clin Endocrinol Metab 2010; 95:2061-2063
9. Machens A, Hauptmann S, Dralle H. Lymph node dissection in the lateral neck for completion in central node-positive papillary thyroid cancer. Surgery 2009; 145:176-181.
10. Dralle H, Machens A. Surgical approaches in thyroid cancer and lymph-node metastases. Best Pract Res Clin Endocrinol Metab 2008; 22:971-987
11. Carling T, Long WD 3rd, Udelsman R. Controversy surrounding the role for routine central lymph node dissection for differentiated thyroid cancer. Curr Opin Oncol 2010; 22:30-34.
12. Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery 2006; 140:1000-1005
13. Chiu CG, Strugnell SS, Griffith OL, Jones SJ, Gown AM, Walker B, Nabi IR, Wiseman SM. Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 2010; 176:2067-2081.
14. Griffith OL, Chiu CG, Gown AM Jones SJ, Wiseman SM. Biomarker panel diagnosis of thyroid cancer: a critical review. Expert Rev Anticancer Ther 2008;8:1399-1413.
15. Lee SH, Lee JK, Jin SM Lee KC, Sohn JH, Chae SW, Kim DH. Expression of cell-cycle regulators (cyclin D1, cyclin E, p27kip1, p57kip2) in papillary thyroid carcinoma. Otolaryngol Head Neck Surg 2010;142:332-337.
16. Liang H, Zhong Y, Luo Z, Huang Y, Lin H, Luo M, Zhan S, Xie K, Ma Y, Li QQ. Assessment of biomarkers for clinical diagnosis of papillary thyroid carcinoma with distant metastasis. Int J Biol Markers 2010; 25:38-45.
17. Huang S. Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res 2007;13:1362-1366.
18. Barbieri I, Pensa S, Pannellini T, Quaglino E, Maritano D, Demaria M, Voster A, Turkson J, Cavallo F, Watson CJ, Provero P, Musiani P, Poli V. Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res 2010; 70:2558-2567.
19. Devarajan E, Huang S. STAT3 as a central regulator of tumor metastases. Curr Mol Med 2009; 9:626-633.
20. Mitsiades CS, Hayden P, Kotoula V, McMillin DW, McMullan C, Negri J, Delmore JE, Poulaki V, Mitsiades N. Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition. J Clin Endocrinol Metab 2007; 92:4845-4852.
21. Antonaci A, Consorti F, Mardente S, Natalizi S, Giovannone G, Della Rocca C. Survivin and cyclin D1 are jointly expressed in thyroid papillary carcinoma and microcarcinoma. Oncol Rep 2008;20:63-67.
22. Londero SC, Godballe C, Krogdahl A, Bastholt L, Specht L, Sørensen CH, Pedersen HB, Pedersen U, Christiansen P. Papillary microcarcinoma of the thyroid gland: is the immunohistochemical expression of cyclin D1 or galectin-3 in primary tumour an indicator of metastatic disease? Acta Oncol 2008;47:451-457.
23. Zhang HY, Meng X, Du ZX, Fang CQ, Liu GL, Wang HQ, Deng WW. Significance of survivin, caspase-3, and VEGF expression in thyroid carcinoma. Clin Exp Med 2009;9:207-213.
24. Rosen DG, Mercado-Uribe I, Yang G, Bast RC Jr, Amin HM, Lai R, Liu J. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 2006; 107:2730-2740
25. Dien J, Amin HM, Chiu N, Wong W, Frantz C, Chiu B, Mackey JR, Lai R. Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer. Am J Pathol 2006; 169:633-642.
26. Hwang JH, Kim DW, Suh JM, Kim H, Song JH, Hwang ES, Hwang IY, Park KC, Chung HK, Kim JM, Park J, Hemmings BA, Shong M. Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/ papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation. Mol Endocrinol 2003; 17:1155-1166
27. Kim YR, Byun HS, Won M, Park KA, Kim JM, Choi BL, Lee H, Hong JH, Park J, Seok JH, Kim DW, Shong M, Park SK, Hur GM. Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/ PTC. BMC Cancer 2008; 8:144-152
28. DeLellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol. 2006;94:662-669.
29. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 2008;21:37-43.
30. Lang SA, Schachtschneider P, Moser C, Mori A, Hackl C, Gaumann A, Batt D, Schlitt HJ, Geissler EK, Stoeltzing O. Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes. Mol Cancer Ther 2008;7:3509-3518.
31. Wang XH, Liu BR, Qu B, Xing H, Gao SL Yin JM, Wang XF, Cheng YQ. Silencing STAT3 may inhibit cell growth through regulating signaling pathway, telomerase, cell cycle, apoptosis and angiogenesis in hepatocellular carcinoma: potential uses for gene therapy. Neoplasma 2011;58:158-171.